{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:08:42Z","timestamp":1792372122964,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["NSFC82000169"],"award-info":[{"award-number":["NSFC82000169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"crossref","award":["cstc2020jcyj-msxmX1058"],"award-info":[{"award-number":["cstc2020jcyj-msxmX1058"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06342-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T06:50:02Z","timestamp":1766472602000},"page":"6175-6186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effects of adding decitabine to conditioning regimen for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Chengxin","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangtao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqun","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangnian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"10147","key":"6342_CR1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE (2018) Acute myeloid leukaemia. Lancet (London England) 392(10147):593\u2013606","journal-title":"Lancet (London England)"},{"issue":"14","key":"6342_CR2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","volume":"383","author":"M Cazzola","year":"2020","unstructured":"Cazzola M (2020) Myelodysplastic syndromes. N Engl J Med 383(14):1358\u20131374","journal-title":"N Engl J Med"},{"issue":"1","key":"6342_CR3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D (2016) Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127(1):62\u201370","journal-title":"Blood"},{"issue":"8","key":"6342_CR4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/bmt.2017.8","volume":"52","author":"B Gyurkocza","year":"2017","unstructured":"Gyurkocza B, Lazarus HM, Giralt S (2017) Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transpl 52(8):1083\u20131090","journal-title":"Bone Marrow Transpl"},{"issue":"13","key":"6342_CR5","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I et al (2017) Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 129(13):1753\u20131762","journal-title":"Blood"},{"issue":"3","key":"6342_CR6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","volume":"124","author":"B Gyurkocza","year":"2014","unstructured":"Gyurkocza B, Sandmaier BM (2014) Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 124(3):344\u2013353","journal-title":"Blood"},{"issue":"19","key":"6342_CR7","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","volume":"35","author":"N Kr\u00f6ger","year":"2017","unstructured":"Kr\u00f6ger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, H\u00fcbel K et al (2017) Dose-Reduced versus standard conditioning followed by allogeneic Stem-Cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncology: Official J Am Soc Clin Oncol 35(19):2157\u20132164","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"11","key":"6342_CR8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL et al (2017) Myeloablative versus Reduced-Intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncology: Official J Am Soc Clin Oncol 35(11):1154\u20131161","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"12","key":"6342_CR9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u20131152","journal-title":"N Engl J Med"},{"issue":"9","key":"6342_CR10","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/leu.2014.124","volume":"28","author":"AP Im","year":"2014","unstructured":"Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE et al (2014) DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia 28(9):1774\u20131783","journal-title":"Leukemia"},{"issue":"12","key":"6342_CR11","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/ajh.26667","volume":"97","author":"NJ Short","year":"2022","unstructured":"Short NJ, Kantarjian H (2022) Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions. Am J Hematol 97(12):1616\u20131626","journal-title":"Am J Hematol"},{"issue":"21","key":"6342_CR12","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncology: Official J Am Soc Clin Oncol 30(21):2670\u20132677","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"21","key":"6342_CR13","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA, Fronick CC, O\u2019Laughlin M, Fulton RS et al (2016) TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023\u20132036","journal-title":"N Engl J Med"},{"issue":"3","key":"6342_CR14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.leukres.2009.08.014","volume":"34","author":"BC Valdez","year":"2010","unstructured":"Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS (2010) 5-Aza-2\u2019-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 34(3):364\u2013372","journal-title":"Leuk Res"},{"key":"6342_CR15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.exphem.2018.08.002","volume":"67","author":"BC Valdez","year":"2018","unstructured":"Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U et al (2018) Epigenetic modification enhances the cytotoxicity of Busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol 67:49\u201359e1","journal-title":"Exp Hematol"},{"issue":"5","key":"6342_CR16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","volume":"24","author":"EA Griffiths","year":"2018","unstructured":"Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J et al (2018) NY-ESO-1 vaccination in combination with decitabine induces Antigen-Specific T-lymphocyte responses in patients with myelodysplastic syndrome. Clin cancer Research: Official J Am Association Cancer Res 24(5):1019\u20131029","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"6342_CR17","doi-asserted-by":"crossref","unstructured":"Cruijsen M, Hobo W, van der Velden W, Bremmers MEJ, Woestenenk R, B\u00e4r B et al (2016) Addition of 10-Day decitabine to fludarabine\/total body irradiation conditioning is feasible and induces Tumor-Associated Antigen-Specific T cell responses. Biology of blood and marrow transplantation: journal of the American society for blood and marrow transplantation. 22(6):1000\u20131008","DOI":"10.1016\/j.bbmt.2016.02.003"},{"issue":"8","key":"6342_CR18","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41409-021-01272-3","volume":"56","author":"M Cruijsen","year":"2021","unstructured":"Cruijsen M, Hilberink JR, van der Velden WJFM, Jansen JH, B\u00e4r B, Schaap NPM et al (2021) Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(8):1964\u20131970","journal-title":"Bone Marrow Transplant"},{"key":"6342_CR19","doi-asserted-by":"crossref","unstructured":"Cao YG, He Y, Zhang SD, Liu ZX, Zhai WH, Ma QL et al (2020) Conditioning regimen of 5-Day decitabine administration for allogeneic stem cell transplantation in patients with myelodysplastic syndrome and myeloproliferative neoplasms. Biology of blood and marrow transplantation: journal of the American society for blood and marrow transplantation. 26(2):285\u2013291","DOI":"10.1016\/j.bbmt.2019.09.001"},{"key":"6342_CR20","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed) 372:n71","journal-title":"BMJ (Clinical Res ed)"},{"key":"6342_CR21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16","journal-title":"Trials"},{"key":"6342_CR22","unstructured":"Higgins JPT, Churchill R, Chandler J, Cumpston MS (2017) Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, Available from www.training.cochrane.org\/handbook"},{"key":"6342_CR23","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al (2021) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"6342_CR24","doi-asserted-by":"crossref","unstructured":"Baker M, Andrews T, Rowley SD, Pecora AL, Skarbnik AP, Vesole DH et al (2016) 5-day decitabine with mini fludarabine and Busulfan yields comparable outcomes to mini flu\/bu but with increased incidence of severe acute GvHD. Blood.;128(22)","DOI":"10.1182\/blood.V128.22.3422.3422"},{"key":"6342_CR25","doi-asserted-by":"crossref","unstructured":"Li Y, Cheng L, Xu C, Chen J, Hu J, Liu N et al (2021) A retrospective observation of treatment outcomes using Decitabine-Combined standard conditioning regimens before transplantation in patients with relapsed or refractory acute myeloid leukemia. Front Oncol.;11","DOI":"10.3389\/fonc.2021.702239"},{"key":"6342_CR26","doi-asserted-by":"crossref","unstructured":"Li Z, Shi W, Lu X, Lu H, Cao X, Tang L et al (2022) Decitabine-Intensified modified Busulfan\/Cyclophosphamide conditioning regimen improves survival in acute myeloid leukemia patients undergoing related donor hematopoietic stem cell transplantation: A propensity score matched analysis. Front Oncol.;12","DOI":"10.3389\/fonc.2022.844937"},{"issue":"7","key":"6342_CR27","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41409-021-01238-5","volume":"56","author":"X Tang","year":"2021","unstructured":"Tang X, Valdez BC, Ma Y, Zhang Q, Qu C, Dai H et al (2021) Low-dose decitabine as part of a modified Bu-Cy conditioning regimen improves survival in AML patients with active disease undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 56(7):1674\u20131682","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"6342_CR28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ajh.26903","volume":"98","author":"Y Tang","year":"2023","unstructured":"Tang Y, Zhang Z, Liu S, Yao Y, Pan T, Qi J et al (2023) Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. Am J Hematol 98(6):881\u2013889","journal-title":"Am J Hematol"},{"key":"6342_CR29","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.2147\/CMAR.S229768","volume":"11","author":"QY Wang","year":"2019","unstructured":"Wang QY, Li Y, Liang ZY, Yin Y, Liu W, Wang Q et al (2019) Decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with intermediate-and high-risk myelodysplastic syndrome\/acute myeloid leukemia: potential decrease in the incidence of acute graft versus host disease. Cancer Manage Res 11:10195\u201310203","journal-title":"Cancer Manage Res"},{"issue":"3","key":"6342_CR30","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S2352-3026(22)00375-1","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Dai M, Jiang E, Wang Y, Huang F, Fan Z et al (2023) The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic Haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 10(3):e178\u2013e90","journal-title":"Lancet Haematol"},{"issue":"6","key":"6342_CR31","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jcpt.13231","volume":"45","author":"W Yao","year":"2020","unstructured":"Yao W, Chu X, Fang X, Zhu X, Tang B, Wan X et al (2020) Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia\/myelodysplastic syndrome not in remission. J Clin Pharm Ther 45(6):1372\u20131381","journal-title":"J Clin Pharm Ther"},{"key":"6342_CR32","doi-asserted-by":"crossref","unstructured":"Zhang R, Lu X, Tang LV, Wang HF, Yan H, You Y et al (2022) Comparative analysis of decitabine intensified BUCY2 and BUCY2 conditioning regimen for high-risk MDS patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant","DOI":"10.1038\/s41409-022-01645-2"},{"key":"6342_CR33","unstructured":"Zhang R, Lu X, Yan H, Wang HF, You Y, Zhong ZD et al (2021) Strategies of Lowering relapse after allogeneic hematopoietic stem cell transplantation for high-risk myelodysplastic syndrome. Chin J Organ Transpl.;42(4)"},{"issue":"7","key":"6342_CR34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/sj.bmt.1704867","volume":"35","author":"SS Farag","year":"2005","unstructured":"Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B et al (2005) High-dose Busulfan, cyclophosphamide, and Etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia. Bone Marrow Transpl 35(7):653\u2013661","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"6342_CR35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ajh.26800","volume":"98","author":"H Liu","year":"2023","unstructured":"Liu H, Huang F, Zhang Y, Wu M, Xu N, Fan Z et al (2023) Idarubicin plus bucy versus bucy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: an open-label, multicenter, randomized phase 3 trial. Am J Hematol 98(3):408\u2013412","journal-title":"Am J Hematol"},{"key":"6342_CR36","doi-asserted-by":"crossref","unstructured":"Shi YY, Su L, Liu ZY, Cao YG, Chen X, Zhang RL et al (2023) A 7-day decitabine included conditioning regimen accelerated donor hematopoietic engraftment while reduced the occurrence of mucositis without interfering with prognosis. Chemotherapy","DOI":"10.1159\/000530381"},{"key":"6342_CR37","doi-asserted-by":"crossref","first-page":"106419","DOI":"10.1016\/j.leukres.2020.106419","volume":"96","author":"CR D\u2019Angelo","year":"2020","unstructured":"D\u2019Angelo CR, Hall A, Woo KM, Kim K, Longo W, Hematti P et al (2020) Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. Leuk Res 96:106419","journal-title":"Leuk Res"},{"issue":"10","key":"6342_CR38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.exphem.2012.06.001","volume":"40","author":"BC Valdez","year":"2012","unstructured":"Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE et al (2012) Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 40(10):800\u2013810","journal-title":"Exp Hematol"},{"issue":"1","key":"6342_CR39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.canlet.2012.12.009","volume":"331","author":"S Vijayaraghavalu","year":"2013","unstructured":"Vijayaraghavalu S, Labhasetwar V (2013) Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion. Cancer Lett 331(1):122\u2013129","journal-title":"Cancer Lett"},{"issue":"10","key":"6342_CR40","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/ijc.34419","volume":"152","author":"X Tong","year":"2023","unstructured":"Tong X, Li M, Jin J, Li Y, Li L, Peng Y et al (2023) Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Int J Cancer 152(10):2123\u20132133","journal-title":"Int J Cancer"},{"issue":"4","key":"6342_CR41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G et al (2019) Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 25(4):603\u2013611","journal-title":"Nat Med"},{"issue":"24","key":"6342_CR42","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ et al (2018) Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med 379(24):2330\u20132341","journal-title":"N Engl J Med"},{"issue":"2","key":"6342_CR43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.1452","volume":"94","author":"A Serrano","year":"2001","unstructured":"Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F et al (2001) Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2\u2019-deoxycytidine treatment. Int J Cancer 94(2):243\u2013251","journal-title":"Int J Cancer"},{"issue":"11","key":"6342_CR44","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-06-3091","volume":"13","author":"E Fonsatti","year":"2007","unstructured":"Fonsatti E, Nicolay HJ, Sigalotti L, Calabr\u00f2 L, Pezzani L, Colizzi F et al (2007) Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2\u2019-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin cancer Research: Official J Am Association Cancer Res 13(11):3333\u20133338","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"11","key":"6342_CR45","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.22141","volume":"86","author":"D Atanackovic","year":"2011","unstructured":"Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y et al (2011) Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol 86(11):918\u2013922","journal-title":"Am J Hematol"},{"issue":"2","key":"6342_CR46","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1158\/0008-5472.CAN-05-3020","volume":"66","author":"ZS Guo","year":"2006","unstructured":"Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y et al (2006) De Novo induction of a cancer\/testis antigen by 5-aza-2\u2019-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66(2):1105\u20131113","journal-title":"Cancer Res"},{"issue":"5","key":"6342_CR47","doi-asserted-by":"crossref","first-page":"e62924","DOI":"10.1371\/journal.pone.0062924","volume":"8","author":"LX Wang","year":"2013","unstructured":"Wang LX, Mei ZY, Zhou JH, Yao YS, Li YH, Xu YH et al (2013) Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLoS ONE 8(5):e62924","journal-title":"PLoS ONE"},{"key":"6342_CR48","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12885-016-2405-z","volume":"16","author":"M Scarpa","year":"2016","unstructured":"Scarpa M, Scarpa M, Castagliuolo I, Erroi F, Basato S, Brun P et al (2016) CD80 down-regulation is associated to aberrant DNA methylation in non-inflammatory colon carcinogenesis. BMC Cancer 16:388","journal-title":"BMC Cancer"},{"issue":"2","key":"6342_CR49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","volume":"131","author":"J Cany","year":"2018","unstructured":"Cany J, Roeven MWH, Hoogstad-van Evert JS, Hobo W, Maas F, Franco Fernandez R et al (2018) Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD\/SCID\/IL2Rg(null) mice. Blood 131(2):202\u2013214","journal-title":"Blood"},{"issue":"3\u20134","key":"6342_CR50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.molimm.2012.12.012","volume":"54","author":"LM Kopp","year":"2013","unstructured":"Kopp LM, Ray A, Denman CJ, Senyukov VS, Somanchi SS, Zhu S et al (2013) Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions. Mol Immunol 54(3\u20134):296\u2013301","journal-title":"Mol Immunol"},{"issue":"36","key":"6342_CR51","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J et al (2020) Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with High-Risk MRD-Negative AML after HSCT: an Open-Label, multicenter, randomized controlled trial. J Clin Oncology: Official J Am Soc Clin Oncol 38(36):4249\u20134259","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"1","key":"6342_CR52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","volume":"116","author":"J Choi","year":"2010","unstructured":"Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E et al (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116(1):129\u2013139","journal-title":"Blood"},{"issue":"9","key":"6342_CR53","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.4049\/jimmunol.1502399","volume":"198","author":"ML Cooper","year":"2017","unstructured":"Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA et al (2017) Azacitidine mitigates graft-versus-host disease via differential effects on the proliferation of T effectors and natural regulatory T cells in vivo. J Immunol 198(9):3746\u20133754","journal-title":"J Immunol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06342-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06342-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06342-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:04Z","timestamp":1767485704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06342-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6342"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06342-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}